These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26561399)

  • 1. P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation.
    Chan MV; Knowles RB; Lundberg MH; Tucker AT; Mohamed NA; Kirkby NS; Armstrong PC; Mitchell JA; Warner TD
    Br J Clin Pharmacol; 2016 Apr; 81(4):621-33. PubMed ID: 26561399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of cyclic nucleotide modulators with P2Y
    Armstrong PC; Ferreira PM; Chan MV; Lundberg Slingsby MH; Crescente M; Shih CC; Kirkby NS; Hobbs AJ; Warner TD
    J Thromb Haemost; 2020 Jul; 18(7):1705-1713. PubMed ID: 32278335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
    Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
    Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
    Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
    J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
    Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
    J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
    Hauguel-Moreau M; Boccara F; Boyd A; Salem JE; Brugier D; Curjol A; Hulot JS; Kerneis M; Galier S; Cohen A; Montalescot G; Collet JP; Silvain J
    Eur Heart J; 2017 Jun; 38(21):1676-1686. PubMed ID: 28065907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels.
    Lundberg Slingsby MH; Gliemann L; Thrane M; Rytter N; Egelund J; Chan MV; Armstrong PC; Warner TD; Hellsten Y
    Acta Physiol (Oxf); 2018 May; 223(1):e13028. PubMed ID: 29297976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet inhibition by P2Y
    Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
    Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
    Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
    J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
    Armstrong PC; Leadbeater PD; Chan MV; Kirkby NS; Jakubowski JA; Mitchell JA; Warner TD
    J Thromb Haemost; 2011 Mar; 9(3):552-61. PubMed ID: 21143373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
    Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
    Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
    Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
    Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.